SARS-CoV-2感染与重症内科患者ICU获得性念珠菌血症的关系:一项多中心前瞻性队列研究
该多中心前瞻性队列利用REA-REZO网络纳入2020年1月至2023年1月入住101个ICU至少48小时的内科成人患者,共55,268例,其中13,472例SARS-CoV-2阳性,284例发生ICU获得性念珠菌血症(ICAC)。采用非简约倾向性评分匹配后,COVID-19患者ICAC发生率仍高于非COVID-19患者(0.8%(93/12,241) vs 0.5%(57/12,241);p=0.004),总体人群为0.8%(107/13,472) vs 0.4%(173/41,796);p<0.001。ICAC发病率COVID-19患者为0.51/1000患者日,非COVID-19患者为0.32/1000患者日,发病率比1.58(95%CI 1.08-2.35;p=0.018)。发生ICAC的患者ICU死亡率更高(49.6% vs 20.2%;p<0.001)。
要点
- 匹配后COVID-19患者ICAC发生率0.8%(93/12,241)高于非COVID-19患者0.5%(57/12,241),p=0.004。
- COVID-19患者ICAC发病率为0.51/1000患者日,非COVID-19患者为0.32/1000患者日,发病率比1.58(95%CI 1.08-2.35;p=0.018)。
- 总体人群中COVID-19患者ICAC发生率0.8%(107/13,472)高于非COVID-19患者0.4%(173/41,796),p<0.001。
- 发生ICAC的患者ICU死亡率为49.6%,无ICAC患者为20.2%(p<0.001)。
- 研究采用非简约倾向性评分匹配控制混杂,并在COVID-19患者中用Fine-Gray模型评估ICAC相关因素。
适用人群与场景
- 2020年1月至2023年1月入住参与REA-REZO网络的101个ICU、因内科原因入院且住院至少48小时的成人患者。
研究设计与关键结果
- 多中心前瞻性队列,纳入101个ICU的55,268例因内科原因住院至少48小时的患者,其中13,472例SARS-CoV-2阳性,284例发生ICAC。
- 总体人群ICAC发生率:COVID-19患者0.8%(107/13,472) vs 非COVID-19患者0.4%(173/41,796);p<0.001。
- 非简约倾向性评分匹配后ICAC发生率:COVID-19患者0.8%(93/12,241) vs 非COVID-19患者0.5%(57/12,241);p=0.004。
- ICAC发病率:COVID-19患者0.51/1000患者日 vs 非COVID-19患者0.32/1000患者日;发病率比1.58(95%CI 1.08-2.35);p=0.018。
- ICAC患者ICU死亡率49.6% vs 无ICAC患者20.2%;p<0.001。
- 采用Fine-Gray模型评估COVID-19患者中与ICAC相关的因素。
证据类型、等级与局限
- 证据类型:多中心前瞻性队列研究。
- 采用非简约倾向性评分匹配控制混杂。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在这大队列中COVID-19患者ICAC发生率虽仍低但高于非COVID-19患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: While SARS-CoV2 infection has been shown to be a significant risk-factor for several secondary bacterial, viral and Aspergillus infections, its impact on intensive care unit (ICU)-acquired candidemia (ICAC) remains poorly explored.
METHOD: Using the REA-REZO network (French surveillance network of ICU-acquired infections), we included all adult patients hospitalized for a medical reason of admission in participating ICUs for at least 48 h from January 2020 to January 2023. To account for confounders, a non-parsimonious propensity score matching was performed. Rates of ICAC according to SARS-CoV2 status were compared in matched patients. Factors associated with ICAC in COVID-19 patients were also assessed using a Fine-Gray model.
RESULTS: A total of 55,268 patients hospitalized at least 48 h for a medical reason in 101 ICUs were included along the study period. Of those, 13,472 were tested positive for a SARS-CoV2 infection while 284 patients developed an ICAC. ICAC rate was higher in COVID-19 patients in both the overall population and the matched patients' cohort (0.8% (107/13,472) versus 0.4% (173/41,796); p < 0.001 and 0.8% (93/12,241) versus 0.5% (57/12,241); p = 0.004, respectively). ICAC incidence rate was also higher in those patients (incidence rate 0.51 per 1000 patients-days in COVID-19 patients versus 0.32 per 1000 patients-days; incidence rate ratio: 1.58 [95% CI:1.08-2.35]; p = 0.018). Finally, patients with ICAC had a higher ICU mortality rate (49.6% versus 20.2%; p < 0.001).
CONCLUSION: In this large multicenter cohort of ICU patients, although remaining low, the rate of ICAC was higher among COVID-19 patients.
参考来源
- Reizine F, Massart N, Mansour A, et al. Relationship between SARS-CoV-2 infection and ICU-acquired candidemia in critically ill medical patients: a multicenter prospective cohort study. Crit Care. 2024. PMID: 39334254. doi:10.1186/s13054-024-05104-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。